Join us for two upcoming talks from early career scientists who are advancing research in areas supported by DCP.  

Monday, May 12
11:00 a.m. – 12:00 p.m. ET
Advance registration required

Xiaoshuang Feng, Ph.D., scientist at the International Agency for Research on Cancer (IARC) will give a talk on “Personalized Risk in Lung Screening.”

Monday, May 19
11:00 a.m. – 12:00 p.m. ET
Advance registration required

Doratha "Armen" Byrd, Ph.D., M.P.H., from the Moffitt Cancer Center will present “Harnessing Studies of Diet and the Gut Microbiome to Reduce Colorectal Cancer Burden.”

Tuesday, June 25 – Friday, June 27
London, UK

Register by Friday, May 9 for the discounted Early Bird rate.

Join researchers from around the world at the Cancer Prevention Research Conference to discuss big questions facing cancer prevention with the brightest minds in prevention research. Over three days, participants will engage with the latest science and perspectives from leaders across the research continuum and make connections that inspire novel ideas and accelerate cancer prevention research.

Thursday, July 24, 2025
8:45 a.m. – 4:45 p.m. ET
Advance registration required

Registration Deadline: May 16, 2025.

Learn from experts in the fields of cancer prevention and interception at the upcoming NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Annual Summit. Presenters will assess the present landscape of research and pinpoint critical challenges and opportunities for the clinical application of precision methods in cancer prevention and interception.

The ultimate goals of CAP-IT are to advance newly discovered cancer preventive or interceptive agents to the existing NCI Division of Cancer Prevention preclinical and clinical development pipelines, PREVENT Cancer Preclinical Drug Development Program (PREVENT), and Cancer Prevention Clinical Trials Network (CP-CTNet).

A draft agenda is available on the registration page.

For more information on CAP-IT, visit NCICAP-IT.org or email CAP-IT@nih.gov.

Are you someone actively looking for resources to bolster your research in cancer preventive agent development? The NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program that supports the preclinical development of innovative interventions and predictive biomarkers for cancer prevention and interception towards clinical applications in high-risk populations. All interested researchers from academia, industry, non-profits, and government with innovative ideas in precision cancer prevention are encouraged to apply. 

2025 Deadlines: Monday, June 2 and November 3, 2025. 

PREVENT’s research priority areas are: 

• Immunoprevention
• Chemoprevention
• Clinically translatable, response-predictive biomarkers

For more information on Program support, types of supported projects, and the application visit the PREVENT web page.

Through this Notice of Funding Opportunity (NOFO), NCI intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention.

RFA-CA-25-013

Expires: June 14, 2025